Federico Gulluni Selected Research

Excipients (Suspending Agents)

11/2019

Downregulation of class II phosphoinositide 3-kinase PI3K-C2β delays cell division and potentiates the effect of docetaxel on cancer cell growth.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Federico Gulluni Research Topics

Disease

6	Neoplasms (Cancer) 07/2021 - 01/2013
2	Breast Neoplasms (Breast Cancer) 01/2022 - 07/2021
2	Neoplasm Metastasis (Metastasis) 01/2022 - 07/2015
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2023
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 11/2019
1	Prostatic Neoplasms (Prostate Cancer) 11/2019
1	Cystic Kidney Diseases (Cystic Kidney Disease) 04/2016
1	Cysts 04/2016
1	Ischemia 04/2016
1	Carcinogenesis 07/2015
1	Thyroid Neoplasms (Thyroid Cancer) 07/2015

Drug/Important Bio-Agent (IBA)

5	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2022 - 09/2014
3	LipidsIBA 01/2023 - 07/2015
2	phosphoinositide-3,4-bisphosphateIBA 01/2022 - 01/2020
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2020 - 07/2015
1	Phosphotransferases (Kinase)IBA 01/2020
1	TOR Serine-Threonine KinasesIBA 01/2020
1	Protein Isoforms (Isoforms)IBA 11/2019
1	Docetaxel (Taxotere)FDA Link 11/2019
1	Excipients (Suspending Agents)IBA 11/2019
1	EnzymesIBA 04/2016
1	polycystic kidney disease 1 proteinIBA 04/2016
1	RacivirIBA 07/2015
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2013

Therapy/Procedure

3	Therapeutics 01/2022 - 09/2014